iBio, Inc. (Nasdaq: IBIO), an innovator in precision antibody therapies, has announced the commencement of an underwritten public offering. This offering includes pre-funded warrants to purchase shares of the company's common stock, as well as accompanying Series G and Series H warrants. All securities in this offering will be sold by iBio. The proceeds from the offering are intended to advance iBio's preclinical cardiometabolic programs, including the IBIO-610 and IBIO-600 programs, through key development milestones, and to support other preclinical pipeline assets. Any remaining funds will be used for working capital and general corporate purposes. Leerink Partners is leading the offering as the bookrunning manager, with LifeSci Capital and Oppenheimer & Co. also serving as bookrunning managers. Brookline Capital Markets is acting as a financial advisor to iBio.